Summary
Homeostasis in vertebrates is tightly regulated by cell death as well as by cell proliferation. The death of cells during embryogenesis, metamorphosis, endocrine-dependent tissue atrophy, and normal tissue turnover is “programmed cell death”, mediated by a process called “apoptosis”. Cytotoxic T lymphocytes and natural killer cells kill the target cells by inducing apoptosis. Apoptosis can be distinguished from necrosis, which occurs as a result of injury, complement attack, severe hypoxia and hyperthermia. Morphological and biochemical analyses of the apoptotic cell death process indicated that apoptosis is accompanied by condensation of cytoplasm, loss of plasma membrane microvilli, segmentation of nucleus, and extensive degradation of chromosomal DNA into oligomers of 180 bp. Cellular proliferation and differentiation are mediated by a family of proteins called cytokines. Our studies on the Fas ligand and Fas have indicated that apoptosis is also mediated by a cytokine and its receptor in some cases. Here, I summarize the current status of the Fas death factor system.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
S. Yonehara, A. Ishii, and M. Yonehara. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169: 1747 (1989).
N. Itoh, S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Sameshima, A. Hase, Y. Seto, and S. Nagata. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233 (1991).
S. Nagata, and P. Golstein. The Fas death factor. Science 267: 1449 (1995).
R. Watanabe-Fukunaga, C.I. Brannan, N. Itoh, S. Yonehara, N.G. Copeland, N.A. Jenkins, and S. Nagata. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148: 1274 (1992).
E. Rouvier, M.-F. Luciani, and P. Golstein. Fas involvement in Cat+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177: 195 (1993).
T. Suda, and S. Nagata. Purification and characterization of the Fas ligand that induces apoptosis. J. Exp. Med. 179: 873 (1994).
T. Suda, T. Takahashi, P. Golstein, and S. Nagata. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75: 1169 (1993).
T. Griffith, T. Brunner, S. Fletcher, D. Green, and T. Ferguson. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189 (1995).
D. Pennica, G.E. Nedwin, J.S. Hayflick, P.H. Seeburg, R. Derynck, M.A. Palladino, W.J. Kohr, B.B. Aggarwal, and D.V. Goeddel. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312: 724 (1984).
M. Tanaka, T. Suda, T. Takahashi, and S. Nagata. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBOJ. 14: 1129 (1995).
M. Tanaka, T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, K. Hatake, A. Drummond, and S. Nagata. Fas ligand in human serum. Nature Medicine 2: 317 (1996).
B.C. Trauth, C. Klas, A.M.J. Peters, S. Matzuku, P. Möller, W. Falk, K.-M. Debatin, and P.H. Krammer. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301 (1989).
J. Dhein, P.T. Daniel, B.C. Trauth, A. Oehm, P. Möller, and P.H. Krammer. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 149: 3166 (1992).
N. Itoh, and S. Nagata. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J. Biol. Chem. 268: 10932 (1993).
L.A. Tartaglia, T.M. Ayres, G.H.W. Wong, and D.V. Goeddel. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74: 845 (1993).
K. Schulze-Osthoff, H. Walczak, W. Dröge, and P.H. Krammer. Cell nucleus and DNA fragmentation are not required for apoptosis. J. Cell Biol. 127: 15 (1994).
A.M. Chinnaiyan, K. O’Rourke, M. Tewari, and V.M. Dixit. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505 (1995).
B.Z. Stanger, P. Leder, T.-H. Lee, E. Kim, and B. Seed. RIP: A novel protein containing a death domain that interacts with FAS/APO-1 (CD95) in yeast and causes cell death. Cell 81: 513 (1995).
F. Kischkel, S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. Krammer, and M. Peter. Cytotoxicitydependent APO-1 (Fas/CD95)-associated proteins from a death-inducing signaling complex (DISC) with the receptor. EMBOJ. 14: 5579 (1995).
M. Enari, H. Hug, and S. Nagata. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375: 78 (1995).
N. Itoh, Y. Tsujimoto, and S. Nagata. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151: 621 (1993).
I. Rodriguez, K. Matsuura, K. Khatib, J. Reed, S. Nagata, and P. Vassalli. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J. Exp. Med.,in press (1996).
M. Enari, R.V. Talanian, W.W. Wong, and S. Nagata. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature,in press (1996).
M. Enari, A. Hase, and S. Nagata. Apoptosis by a cytosolic extract from Fas-activated cells. EMBO J. 14: 5201 (1995).
T. Suda, T. Okazaki, Y. Naito, T. Yokota, N. Arai, S. Ozaki, K. Nakao, and S. Nagata. Expression of the Fas ligand in T-cell-lineage. J. Immunol. 154: 3806 (1995).
H. Arase, N. Arase, and T. Saito. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181: 1235 (1995).
R. Watanabe-Fukunaga, C.I. Brannan, N.G. Copeland, N.A. Jenkins, and S. Nagata. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314 (1992).
M. Adachi, R. Watanabe-Fukunaga, and S. Nagata. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of 1pr mice. Proc. Natl. Acad. Sci. USA 90: 1756 (1993).
T. Takahashi, M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969 (1994).
S. Nagata, and T. Suda. Fas and Fas ligand: 1pr and gld mutations. Immunol. Today 16: 39 (1995).
D. Watanabe, T. Suda, H. Hashimoto, and S. Nagata. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J 14: 12 (1995).
M. Adachi, S. Suematsu, T. Suda, D. Watanabe, H. Fukuyama, J. Ogasawara, T. Tanaka, N. Yoshida, and S. Nagata. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc. Natl. Acad. Sci. USA 93: 2137 (1996).
D. Watanabe, T. Suda, and S. Nagata. Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Int. Immunology 7: 1949 (1995).
M. Adachi, S. Suematsu, T. Kondo, J. Ogasawara, T. Tanaka, N. Yoshida, and S. Nagata. Targeted mutation in the Fas gene causes hyperplasia in the peripheral lymphoid organs and liver. Nature Genetics 11: 294 (1995).
J. Ogasawara, R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata. Lethal effect of the anti-Fas antibody in mice. Nature 364: 806 (1993).
N. Hiramatsu, N. Hayashi, K. Katayama, K. Mochizuki, Y. Kawanishi, A. Kasahara, H. Fusamoto, and T. Kamada. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19: 1354 (1994).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Nagata, S. (1996). Fas-Mediated Apoptosis. In: Gupta, S., Cohen, J.J. (eds) Mechanisms of Lymphocyte Activation and Immune Regulation VI. Advances in Experimental Medicine and Biology, vol 406. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0274-0_12
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0274-0_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0276-4
Online ISBN: 978-1-4899-0274-0
eBook Packages: Springer Book Archive